# Seventure Partners

> Seventure Partners is a VC fund backing Biotechnology and Health Care. See 247 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 247
- Last investment: Jun 2026
- Lead investor: 36%
- Last fund: Jul 2019
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/seventure-partners
- X (Twitter): https://twitter.com/seventurep
- Website: http://www.seventure.fr
- Facebook: https://www.facebook.com/SeventureP/

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

## Contacts

5 contacts available for Seventure Partners. Shizune tracks 14 team members at Seventure Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/seventure-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.3M–$28M |
| Series B | $3.4M–$63M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 52 | 21% |
| Health Care | 30 | 12% |
| Software | 28 | 11% |
| Information Technology | 18 | 7% |
| Medical Device | 16 | 6% |

171 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 53 | 21% |
| Series B | 42 | 17% |
| Funding Round | 41 | 17% |
| Seed | 31 | 13% |
| Series C | 19 | 8% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 79 | 32% |
| United States | 21 | 9% |
| Germany | 18 | 7% |
| United Kingdom | 6 | 2% |
| Denmark | 5 | 2% |

18 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adrien Caetano | Gestionnaire Middle & Back Office | 0 | https://shizune.co/investors/profile/adrien-caetano |
| Ana Salas | assistant | 0 | https://shizune.co/investors/profile/ana-salas |
| Bruno Rivet | General Partner & Associate Director | 4 | https://shizune.co/investors/profile/bruno-rivet |
| David Manjarres | Head of ICT Department - General Partner | 8 | https://shizune.co/investors/profile/david-manjarres |
| Denise Kelly | Venture Partner | 0 | https://shizune.co/investors/profile/denise-kelly |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Wultra | Wultra provides easy-to-deploy post-quantum authentication solutions for financial institutions, ensuring secure and seamless access to digital services. Our developer-friendly technology, powered by NIST-endorsed quantum-resistant cryptography, delivers bulletproof security, a passwordless user experience, and compliance with global regulations —all deployable in just 8 weeks. Trusted by financial institutions worldwide, Wultra’s solutions meet stringent standards like PSD3/PSR1 and eIDAS 2.0 while offering cutting-edge protection against evolving cyber threats. | $7.8M | Series A | Jun 29, 2026 |  |
| MEDIADS | Mediads is the Operating System for a better Social Marketing. Our platform enables Social Ads Amplification: performance-oriented social campaigns are delivered from media-brand handles via Trusted Social Ads (dark delivery only—never organic, never shown to a publisher’s followers). Advertisers own the setup and the data: campaigns run insidetheir Business Manager, with their pixel and audiences, unlocking reliable full-funnel measurement (ROAS, conversions, sales) and strict budget control. For publishers, Mediads creates incremental EBITDA with zero tech integration (no CMS/JS), zero operational lift, and a simple pre-approval workflow. Our economic model combines a variable fee of media spend with a monthly subscription (catalog access, advisory, day-to-day support). Mediads works with leading media groups and more than 500 brands such as Volvo, American Express, and Levi’s, scaling a trusted bridge between media-brand equity and advertiser performance. | $3.5M | Seed | May 19, 2026 |  |
| Standing Ovation | Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $28.6M | Series B | Mar 31, 2026 |  |
| Zenniz | Zenniz is an ITF approved game tracking solution that provides real-time info, such as automated line calling, stroke and serve speeds, shot charts, match statistics and more. Players and coaches at all levels can use Zenniz on and off the court to help improve their game. For tennis clubs, Zenniz is an easy and cost-effective way to upgrade to thenext level. Due to a new, innovative sensor technology, they’ve been able to keep the cost to a minimum, making Zenniz accessible for all clubs, coaches and players. | $6M | Venture - Series Unknown | Feb 20, 2026 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M | Series B | Feb 09, 2026 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M | Series B | Feb 09, 2026 |  |
| ErVimmune | ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. | $19.9M | Series A | Jan 21, 2026 |  |
| The Sanctuary Group | The Sanctuary Group provides aqua-cycling, indoor cycling, boxing bootcamp, yoga, dance cardio, HIIT workouts, and kids’ swim classes. | $5.5M | Venture - Series Unknown | Jan 12, 2026 |  |
| Playse | Playse is a platform that connects professional football instructors and parents to enroll kids in training sessions around country. | $3.5M | Seed | Oct 22, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |

10 of 247 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 16 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 10 deals together
- [Crédit Mutuel Innovation](https://shizune.co/investors/profile/cm-cic-capital-innovation) — VC Fund, 8 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 8 deals together
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund, 7 deals together
- [XAnge](https://shizune.co/investors/profile/xange-private-equity) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [All Investors in France](https://shizune.co/investors/investors-france)
- [All VC Funds in France](https://shizune.co/investors/vc-funds-france)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does Seventure Partners invest in?

Seventure Partners invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 247 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Seventure Partners's check size?

Seventure Partners typically joins rounds of $3.3M–$28M at Series A and $3.4M–$63M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Seventure Partners participates in.

### How do I contact Seventure Partners?

Public channels for Seventure Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Seventure Partners?

The team at Seventure Partners includes Adrien Caetano (Gestionnaire Middle & Back Office), Ana Salas (assistant) and Bruno Rivet (General Partner & Associate Director), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co